Hallan H, Svarva P L, Svartås T M, Widerøe T
Scand J Infect Dis Suppl. 1981;29:55-8.
Pharmacokinetic properties and clinical efficiency of azlocillin were investigated in three patients with terminal renal failure both during and without haemodialysis. All patients were treated for urinary tract infections with azlocillin 2 g three times daily for a period of ten days. Mean serum half-lives off dialysis were 251 min and on dialysis 202 min. Azlocillin clearances increased from a mean value of 58.7 ml/min off dialysis to 72.6 ml/min on dialysis. Urinary excretion of the total daily dose of azlocillin was less than 5% for all patients, but from day 2 onwards all patients had urine levels which were more than 8 times above the approximate MIC value of the infecting bacteria.
在三名终末期肾衰竭患者进行血液透析期间及未进行血液透析时，研究了阿洛西林的药代动力学特性和临床疗效。所有患者均接受阿洛西林治疗尿路感染，每日三次，每次2 g，疗程为十天。透析期间阿洛西林的平均血清半衰期为251分钟，透析时为202分钟。阿洛西林清除率从透析前的平均值58.7 ml/分钟增加到透析时的72.6 ml/分钟。所有患者阿洛西林每日总剂量的尿排泄量均低于5%，但从第2天起，所有患者的尿液水平均比感染细菌的近似最低抑菌浓度值高出8倍以上。
